

# A Randomized, Double-blind, Placebo-controlled Trial on the Prevention of Chronic Postoperative Pain after Inguinal Hernia and Knee Surgery by Postoperative Treatment with Tapentadol

Gepubliceerd: 27-01-2021 Laatst bijgewerkt: 13-12-2022

We hypothesize that treatment with Tapentadol will reduce the development of chronic postoperative pain by enhancing or maintaining CPM responses and possibly reducing central sensitization. We hypothesize that a 4-week treatment with Tapentadol...

<b>Ethische beoordeling</b>	Positief advies
<b>Status</b>	Werving nog niet gestart
<b>Type aandoening</b>	-
<b>Onderzoekstype</b>	Interventie onderzoek

## Samenvatting

### ID

NL-OMON20334

### Bron

NTR

### Verkorte titel

PREVENT

### Aandoening

Osteoarthritis, knee replacement surgery, inguinal hernia, inguinal hernia surgery.

### Ondersteuning

**Primaire sponsor:** Leiden University Medical Center

**Overige ondersteuning:** Leiden University Medical Center (LUMC), Grunenthal GmbH, Aachen Germany

## Onderzoeksproduct en/of interventie

### Uitkomstmaten

#### Primaire uitkomstmaten

Both CPM and the presence of central sensitization (measured by TS and allodynia) will be measured before and after treatment to evaluate the effect of Tapentadol on these responses.

## Toelichting onderzoek

#### Achtergrond van het onderzoek

Rationale: The development of chronic postoperative pain is not well understood. We recently conducted a large trial in patients who underwent inguinal hernia surgery and investigated whether the pre-operative state of the endogenous pain modulatory system (a central pain modulatory system important for normal pain perception) could predict the development of postoperative chronic pain after inguinal hernia surgery. In this study we demonstrated that a normal functioning endogenous pain modulatory system was predictive for the development of postoperative chronic pain. Tapentadol is an analgesic able to influence the endogenous pain system by maintaining its function and we hypothesize that treatment with tapentadol will reduce the chance to develop postoperative chronic pain.

Objective: To prevent the development of chronic postoperative pain after inguinal hernia surgery and knee replacement surgery and to further explore the mechanism behind the development of chronic postoperative pain.

Study design: A double-blind, randomized, placebo-controlled, non-crossover longitudinal study.

Study population: Patients planned for elective inguinal hernia surgery or knee replacement surgery.

Intervention (if applicable): Postoperative treatment with oral tapentadol sustained release (maximum of 100 mg twice daily) and placebo.

Main study parameters/endpoints: (1) The effect of tapentadol compared to placebo on the development of chronic pain in the first year after surgery; (2) The influence of the pre-operative pain profile on the development of chronic postoperative pain and (3) The influence of tapentadol and placebo on the individual pain profiles and its influence on the development of chronic postoperative pain.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The burden for the patients is that they will take low doses of pain medication for 1 month after surgery and will come to the hospital 2 times for pain testing and questionnaires. The hospital visit will take about 30-45 minutes.

#### Doel van het onderzoek

We hypothesize that treatment with Tapentadol will reduce the development of chronic postoperative pain by enhancing or maintaining CPM responses and possibly reducing central sensitization. We hypothesize that a 4-week treatment with Tapentadol will reduce the risk for these patients to develop chronic postoperative pain in the first year after surgery.

## **Onderzoeksopzet**

After the treatment period the development of chronic pain will be assessed by telephone at 3, 6 and 12 months after the surgery. Pain intensity will be assessed using the numerical rating scale (NRS) and patients will be asked to fill in a pain diary every month where they score the average pain score during rest and during exercise in the last month and last week.

## **Onderzoeksproduct en/of interventie**

Tapentadol or placebo for a 4-week period

## **Contactpersonen**

### **Publiek**

Leiden University Medical Center (LUMC), Department of Anesthesiology, P.O. Box 9600  
Albinusdreef 2 2300 RC Leiden The Netherlands  
Marieke Niesters

Phone: +31 (0)71 5262301

### **Wetenschappelijk**

Leiden University Medical Center (LUMC), Department of Anesthesiology, P.O. Box 9600  
Albinusdreef 2 2300 RC Leiden The Netherlands  
Marieke Niesters

Phone: +31 (0)71 5262301

## **Deelname eisen**

### **Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)**

1. Patients scheduled for elective inguinal hernia surgery(270) or knee replacement surgery

(270)

2. American Society of Anesthesiologists score 1, 2 or 3
3. Age between 18-80 years

## **Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)**

1. Pain scores > 3 (on a 11-point numerical rating scale, NRS) reported for most of the day during the past month (except for knee pain in patients planned for knee replacement surgery);
2. Regular use of anti-depressants or anti-epileptics for any purpose, including SNRIs and gabapentinoids
3. Known allergies or contraindication to the study medication according to the SmPC
4. The presence of any chronic pain disorder (other than chronic knee pain);
5. Pregnancy/lactation;
6. Use of MAO-inhibitors or rifampicin within the last 14 days before inclusion;
7. Inability to perform psychophysical testing
8. Inability to give informed consent;
9. Inability to communicate with the investigators.

## **Onderzoeksopzet**

### **Opzet**

Type:	Interventie onderzoek
Onderzoeksmodel:	Anders
Toewijzing:	Gerandomiseerd
Blinding:	Dubbelblind
Controle:	Placebo

### **Deelname**

Nederland	
Status:	Werving nog niet gestart
(Verwachte) startdatum:	01-03-2021
Aantal proefpersonen:	540
Type:	Verwachte startdatum

## **Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)**

**Wordt de data na het onderzoek gedeeld:** Nog niet bepaald

## **Ethische beoordeling**

Positief advies

Datum: 27-01-2021

Soort: Eerste indiening

## **Registraties**

### **Opgevolgd door onderstaande (mogelijk meer actuele) registratie**

Geen registraties gevonden.

### **Andere (mogelijk minder actuele) registraties in dit register**

Geen registraties gevonden.

## **In overige registers**

### **Register**

NTR-new

Ander register

### **ID**

NL9223

METC LDD : P20.084

## **Resultaten**